Calamos Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.39M | Sell |
12,211
-7,723
| -39% | -$878K | 0.01% | 632 |
|
|
2025
Q1 | $2.1M | Buy |
19,934
+5,519
| +38% | +$580K | 0.01% | 557 |
|
|
2024
Q4 | $1.54M | Sell |
14,415
-49
| -0.3% | -$5.25K | 0.01% | 597 |
|
|
2024
Q3 | $1.45M | Buy |
14,464
+3,617
| +33% | +$362K | 0.01% | 611 |
|
|
2024
Q2 | $914K | Buy |
10,847
+1,812
| +20% | +$153K | ﹤0.01% | 625 |
|
|
2024
Q1 | $660K | Buy |
9,035
+4,449
| +97% | +$325K | ﹤0.01% | 661 |
|
|
2023
Q4 | $328K | Buy |
+4,586
| New | +$328K | ﹤0.01% | 696 |
|
|
2023
Q3 | – | Sell |
-12,619
| Closed | -$910K | – | 932 |
|
|
2023
Q2 | $910K | Sell |
12,619
-11,077
| -47% | -$799K | ﹤0.01% | 689 |
|
|
2023
Q1 | $1.74M | Buy |
23,696
+7,774
| +49% | +$572K | 0.01% | 734 |
|
|
2022
Q4 | $1.06M | Buy |
+15,922
| New | +$1.06M | 0.01% | 826 |
|
|
2019
Q1 | – | Sell |
-2,453
| Closed | -$208K | – | 644 |
|
|
2018
Q4 | $208K | Hold |
2,453
| – | – | ﹤0.01% | 617 |
|
|
2018
Q3 | $420K | Buy |
+2,453
| New | +$420K | ﹤0.01% | 560 |
|